Physiologically-relevant drug screening
Our brain-on-a-chip microfluidic device advances neurological drug development by providing a more accurate drug screening and neurotoxicity testing platform. Unlike traditional 2D cell cultures or animal models, our device mimics the 3D microenvironment of the human brain, particularly the blood-brain barrier (BBB).
The µBrain configuration contains 8 microfluidic devices, while the µBrain-MEA includes a single microelectrode array (MEA) for real-time electrophysiological monitoring. By utilizing neurons, endothelial cells, and stromal cells, our device forms perfusable human blood vessels that simulate the BBB, enabling the assessment of drug delivery and its effects on the brain.
Accelerating Drug Development
By adding drugs into the device similar to their delivery through blood vessels, we can evaluate which compounds cross the BBB and analyze their impact on brain activity through electrical signals recorded by the MEA. This platform accelerates the drug development process, offering clinically relevant results and reducing experimental costs for developers.
Advantages of Our Technology
- Physiological Relevance: Our platform provides physiologically relevant results by accurately mimicking the human brain's microenvironment, including the blood-brain barrier.
- Real-time Monitoring: With the MEA component, our device offers real-time electrophysiological monitoring, providing immediate insights into drug effects on neuronal activity.
- Service-based Model: We offer a service-based model, simplifying operations for our clients and ensuring consistent and reliable results without the need for extensive customer training.
